Financial StabilityMindMed ended with ~$245M of cash, which should provide a cash runway into 2027, ensuring financial stability for ongoing projects.
Pipeline AdvancementEnrollment is on track for the Phase 3 Voyage study for MM120 ODT, indicating progress in the generalized anxiety disorder program.
Regulatory StrategyMM120’s development strategy includes measures intended to mitigate regulatory risks common to psychedelic trials, which may support a potential New Drug Application submission in 2027.